On Nov 07, major Wall Street analysts update their ratings for $Jazz Pharmaceuticals (JAZZ.US)$, with price targets ranging from $140 to $207.
Morgan Stanley analyst Jeffrey Hung maintains with a hold rating, and maintains the target price at $140.
BofA Securities analyst Jason Gerberry maintains with a buy rating, and adjusts the target price from $172 to $182.
Barclays analyst Balaji Prasad maintains with a buy rating, and adjusts the target price from $200 to $190.
TD Cowen analyst Joseph Thome maintains with a buy rating, and adjusts the target price from $200 to $195.
Needham analyst Ami Fadia maintains with a buy rating, and adjusts the target price from $205 to $207.
Furthermore, according to the comprehensive report, the opinions of $Jazz Pharmaceuticals (JAZZ.US)$'s main analysts recently are as follows:
Jazz Pharmaceuticals reported third-quarter revenue in line with expectations and a significant beat on non-GAAP net income, despite facing temporary challenges affecting the Rylaze brand. The overall assessment of the third-quarter results is positive. The company is perceived to be trading at very low multiples, yet is projected to deliver mid-single digit revenue growth and high-single digit earnings growth on an annual compound basis.
Jazz Pharmaceuticals' Q3 revenue surpassed expectations, primarily due to robust performance from its main growth contributors Xywav and Epidiolex. However, Rylaze experienced a temporary setback due to changes in the treatment protocol.
Jazz Pharmaceuticals' total Q3 revenue surpassed expectations, bolstered by strong performances from products including Xywav, Epidiolex, Defitelio, and Zepzelca.
Here are the latest investment ratings and price targets for $Jazz Pharmaceuticals (JAZZ.US)$ from 7 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间11月7日，多家华尔街大行更新了$爵士制药 (JAZZ.US)$的评级，目标价介于140美元至207美元。
摩根士丹利分析师Jeffrey Hung维持持有评级，维持目标价140美元。
美银证券分析师Jason Gerberry维持买入评级，并将目标价从172美元上调至182美元。
巴克莱银行分析师Balaji Prasad维持买入评级，并将目标价从200美元下调至190美元。
TD Cowen分析师Joseph Thome维持买入评级，并将目标价从200美元下调至195美元。
Needham分析师Ami Fadia维持买入评级，并将目标价从205美元上调至207美元。
此外，综合报道，$爵士制药 (JAZZ.US)$近期主要分析师观点如下：
爵士制药报告称，第三季度营业收入符合预期，非通用会计净利润显著优于预期，尽管受到影响Rylaze品牌的暂时性挑战。第三季度业绩整体评估为积极。公司被认为正在以非常低的倍数交易，但据预测，将以复合年度基础上交付中单位数的营业收入增长和高单位数的收益增长。
爵士制药第三季度营收超过预期，主要是由于其主要增长贡献者Xywav和Epidiolex的强劲表现。然而，由于治疗方案的更改，Rylaze遭遇了暂时挫折。
爵士制药第三季度总营收超过预期，得到Xywav、Epidiolex、Defitelio和Zepzelca等产品的强劲表现支撑。
以下为今日7位分析师对$爵士制药 (JAZZ.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
